PT  - JOURNAL ARTICLE
AU  - Jordana Grazziela A. Coelho dos Reis
AU  - Geovane Marques Ferreira
AU  - Alice Aparecida Lourenço
AU  - Ágata Lopes Ribeiro
AU  - Camila Pacheco da Silveira Martins da Mata
AU  - Patrícia de Melo Oliveira
AU  - Daisymara Priscila de Almeida Marques
AU  - Linziane Lopes Ferreira
AU  - Felipe Alves Clarindo
AU  - Murillo Ferreira da Silva
AU  - Heitor Portella Póvoas Filho
AU  - Nilson Roberto Ribeiro Oliveira Junior
AU  - Maisah Meyhr D’Carmo Sodré
AU  - Sandra Rocha Gadelha
AU  - George Rego Albuquerque
AU  - Bianca Mendes Maciel
AU  - Ana Paula Melo Mariano
AU  - Mylene de Melo Silva
AU  - Renato Fontana
AU  - Lauro Juliano Marin
AU  - Renata Santiago Alberto Carlos
AU  - Amanda Teixeira Sampaio Lopes
AU  - Fabrício Barbosa Ferreira
AU  - Uener Ribeiro dos Santos
AU  - Íris Terezinha Santos de Santana
AU  - Hllytchaikra Ferraz Fehlberg
AU  - Rachel Passos Rezende
AU  - João Carlos T Dias
AU  - Eduardo Gross
AU  - Gisele Assis Castro Goulart
AU  - Marie Gabriele Santiago
AU  - Ana Paula Motta Lavigne de Lemos
AU  - Aline O da Conceição
AU  - Carla Cristina Romano
AU  - Luciana Debortoli de Carvalho
AU  - Olindo Assis Martins Filho
AU  - Claudio Almeida Quadros
AU  - Sarah J Valle
AU  - David L Morris
TI  - Ex-vivo mucolytic and anti-inflammatory activity of BromAc in tracheal aspirates from COVID-19
AID  - 10.1101/2021.12.23.21268347
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.23.21268347
4099  - http://medrxiv.org/content/early/2021/12/23/2021.12.23.21268347.short
4100  - http://medrxiv.org/content/early/2021/12/23/2021.12.23.21268347.full
AB  - COVID-19 is a lethal disease caused by the pandemic SARS-CoV-2, which continues to be a public health threat. COVID-19 is principally a respiratory disease and is often associated with sputum retention, for which there are limited therapeutic options. In this regard, we evaluated the use of BromAc®, a combination of Bromelain and Acetylcysteine (NAC). Both drugs present mucolytic effect and have been studied to treat COVID-19. Therefore, we sought to examine the mucolytic, antiviral, and anti-inflammatory effect of BromAc® in tracheal aspirate samples from critically ill COVID-19 patients requiring mechanical ventilation.Method Tracheal aspirate samples from COVID-19 patients were collected following next of kin consent and mucolysis, rheometry and cytokine storm analysis was performed.Results BromAc® displayed a robust mucolytic effect in a dose dependent manner. BromAc® showed anti-inflammatory activity, reducing the action of cytokine storm, chemokines including MIP-1alpha, CXCL8, MIP-1b, MCP-1 and IP-10, and regulatory cytokines IL-5, IL-10, IL-13 IL-1RA and total reduction for IL-9 compared to NAC alone and control. BromAc® acted on IL-6, demonstrating a reduction in G-CSF and VEGF-D at concentrations of 125 and 250µg.Conclusion These results indicate robust mucolytic and anti-inflammatory effect of BromAc® in tracheal aspirates from critically ill COVID-19 patients, indicating its potential as a therapeutic strategy to COVID-19.Competing Interest StatementSJV and DLM are employed by Mucpharm Pty Ltd and provided scientific input on the protocol and design of the study.Funding StatementMucpharm Pty Ltd financially supported this project. In addition, we thank all Brazilian funding agencies CAPES, CNPq and FAPEMIG for providing funding to this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study followed the principles of Helsinki declaration as well as the resolution #466/2012 from the Brazilian Ministry of Health for research involving humans. This investigation was approved by the Santa Cruz State University (UESC) Institutional Brazilian Ethics Committee (Approval number: 45919121.6.0000.5526).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors